We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Ne... Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. The company derives its revenue from Product Sales, fees and; license sources. Show more
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in...
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
0001610853falseDE00016108532024-03-042024-03-04UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the...
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances...
0001610853falseDE00016108532024-02-062024-02-06UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -0.877192982456 | 5.7 | 6.0541 | 5.5 | 8757 | 5.70093433 | CS |
4 | 1.21 | 27.2522522523 | 4.44 | 6.98 | 4.42 | 446061 | 5.78406742 | CS |
12 | -2.41 | -29.9007444169 | 8.06 | 9.5 | 4.29 | 331034 | 6.13072788 | CS |
26 | -3.01 | -34.7575057737 | 8.66 | 9.89 | 4.29 | 160802 | 6.20444683 | CS |
52 | -6.85 | -54.8 | 12.5 | 14.44 | 4.29 | 364233 | 8.53802728 | CS |
156 | -911.35 | -99.3838604144 | 917 | 955 | 4.29 | 682892 | 41.17916015 | CS |
260 | -11841.85 | -99.9523106141 | 11847.5 | 11987.5 | 4.29 | 560901 | 381.16588701 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions